Skip to main content
Medivir logo

Medivir — Investor Relations & Filings

Ticker · MVIR ISIN · SE0020181014 LEI · 549300VWDGUX0WMJ1T79 ST Manufacturing
Open in API
Filings indexed 965 across all filing types
Latest filing 2016-11-02 M&A Activity
Country SE Sweden
Listing ST MVIR

About Medivir

https://www.medivir.com/

Medivir is a pharmaceutical company specializing in the discovery and clinical development of innovative drugs for cancer. The company focuses on oncology areas with high unmet medical needs, aiming to provide transformative treatments for patients with limited therapeutic options. Its research and development strategy is based on extensive expertise in drug design, particularly targeting enzymes such as proteases and polymerases, and includes the use of a proprietary prodrug platform. Medivir actively pursues collaborations with academic and industrial partners to advance its pipeline from research through to commercialization.

Recent filings

Filing Released Lang Actions
Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs
M&A Activity Classification · 98% confidence The document announces a significant corporate action: Medivir entering into an agreement to acquire two clinical stage oncology programs from another company (Tetralogic Pharmaceuticals). It details the assets acquired (remetinostat and birinapant), the financial considerations (upfront payment, milestones, royalties), and strategic rationale. This type of announcement, concerning the acquisition of assets or business units, falls under Merger & Acquisition (M&A) activity. The presence of an invitation to a conference call/webcast suggests this is a major corporate event announcement, but the core content is the transaction itself. Therefore, the most appropriate classification is Transaction/M&A Activity (TAR). It is not a standard earnings release (ER), interim report (IR), or annual report (10-K).
2016-11-02 English
Medivir stärker sin kliniska pipeline genom att teckna avtal om förvärv av en portfölj av onkologiprogram i klinisk fas
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a significant corporate action: the acquisition of two oncology programs (remetinostat and birinapant) from another company (Tetralogic Pharmaceuticals). It details the clinical status, market potential, financial structure of the deal (including upfront payments and milestones), and strategic rationale. Crucially, it concludes with an invitation to a conference call/webcast to discuss the news. This structure—a major corporate announcement followed by an invitation to discuss results—is characteristic of an Earnings Release (ER) or a significant corporate event announcement. Since this is not a routine quarterly financial report (10-K or IR) but a specific, material corporate transaction announcement, and it includes a call invitation, it aligns best with an Earnings Release (ER) which often bundles strategic news with financial context, or potentially a Regulatory Filing (RNS) if it were purely regulatory. However, the detailed nature of the announcement about the acquisition and the inclusion of a call for analysts strongly suggests it is the primary communication vehicle for material, time-sensitive news, fitting the 'Earnings Release' category for major corporate updates, even if not strictly quarterly earnings. Given the options, 'ER' is the closest fit for a major, time-sensitive corporate announcement accompanied by an analyst call invitation.
2016-11-02 Swedish
Medivirs nukleotidbaserade polymerashämmare för behandling av levercancer, MIV-818, går in i preklinisk utvecklingsfas
Regulatory Filings Classification · 92% confidence The document is a press release from Medivir AB announcing that their drug candidate, MIV-818, is entering the preclinical development phase for liver cancer treatment. It details the medical need, the drug's mechanism, and future plans (communicating data at conferences in 2017). The text concludes with contact information and a statement that the information is being made public according to EU market abuse regulation, dated November 1, 2016. This format—a formal announcement of a significant corporate/pipeline event via press release—is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category. Since it is a specific operational/pipeline update rather than a financial summary (ER) or a formal regulatory filing like a 10-K, and it is not a transcript (CT), presentation (IP), or dividend notice (DIV), the most appropriate general category for a significant, non-financial, non-meeting related announcement is Regulatory Filings (RNS), as it serves as a general disclosure mechanism. However, given the content is a major operational update, it often aligns closely with an Earnings Release structure (announcing progress) but lacks the actual financial figures. Since it is a specific, non-financial operational update, RNS is the best fit as a general disclosure mechanism, although it is not a standard financial report.
2016-11-01 Swedish
Medivir’s nucleotide polymerase inhibitor for the treatment of liver cancer, MIV-818, enters non-clinical development
Regulatory Filings Classification · 94% confidence The document is an announcement from Medivir AB regarding a specific drug candidate (MIV-818) entering non-clinical development for liver cancer treatment. It details the medical need, the drug's mechanism, and includes quotes from management. This type of announcement, focusing on R&D progress and pipeline milestones, is characteristic of an investor relations update or a general corporate announcement, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a comprehensive interim report (IR). Since it announces a significant internal development milestone and is clearly aimed at investors, it fits best under the general category of Investor Presentation (IP) if it were a presentation, or more broadly, a corporate update. However, looking at the provided definitions, none perfectly capture a pure R&D pipeline update announcement. It is not a Call Transcript (CT), Earnings Release (ER), or Interim Report (IR). It is not a Director's Dealing (DIRS) or a Major Shareholding Notification (MRQ). Given the context of providing detailed scientific and strategic information to the market, 'Investor Presentation' (IP) is the closest fit for conveying strategic pipeline information, although it is structured as a press release. Since it is a formal announcement of a significant corporate/scientific event, and not a report itself, and doesn't fit other specific categories, it is most likely intended as a general regulatory filing or an announcement that supports investor information. Given the content is a detailed update on a drug candidate, it is a form of investor communication. If we must choose from the list, and recognizing it's a press release detailing R&D progress, it is often categorized alongside Investor Presentations (IP) or sometimes as a Regulatory Filing (RNS) if it doesn't fit elsewhere. Since it is a specific, substantive update, and not just a notice of a report, I will classify it as an Investor Presentation (IP) as it serves that function, or RNS as a fallback. Given the depth of the scientific detail, IP is a strong candidate. However, if this is a standard press release format, RNS (Regulatory Filings/General Announcement) is the safest fallback for non-standard reports. Let's re-evaluate: It is a press release announcing a pipeline milestone. This is standard investor news. It is not a DEF 14A (Remuneration), DVA (Voting Results), or DIV (Dividend). It is most similar in function to an Investor Presentation (IP) in terms of content focus (strategy/pipeline), but it is not formatted as a presentation deck. Therefore, I will use RNS as the most appropriate general regulatory announcement category for substantive, non-standard updates.
2016-11-01 English
MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead
Regulatory Filings Classification · 95% confidence The document is a press release from Medivir AB announcing the completion of enrollment in a Phase IIa clinical trial for MIV-711 and a positive recommendation from the independent Drug Monitoring Committee (DMC). It includes key operational updates, scientific context, market potential, and contact information. Crucially, it ends with the statement: "Medivir is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10.15 CET on 27 October 2016." This structure strongly indicates a general regulatory announcement or press release that doesn't fit the specific financial report categories (like 10-K, IR, ER). Since it is a formal announcement required by securities law that doesn't fit a more specific category (like Director's Dealing, Dividend Notice, or Earnings Release), the most appropriate fallback category is Regulatory Filings (RNS). The document length (3789 chars) is short enough that if it were merely announcing a report, RPA would be considered, but here it is announcing operational progress, making RNS the better fit for a general regulatory disclosure.
2016-10-27 English
Rekryteringen till fas IIa-studien inom artrosprogrammet MIV-711 är slutförd och säkerhetsgranskningskommittén bekräftar fortsättning av studien
Regulatory Filings Classification · 93% confidence The document is a press release from Medivir AB announcing that patient recruitment for a Phase IIa clinical trial (MIV-711 for osteoarthritis) is complete and that the independent data monitoring committee recommended continuing the study based on safety data. It provides details about the trial design, expected data release timeline (Q3 2017), and market potential. This type of announcement, detailing clinical trial progress and safety review outcomes, is typically classified as an Investor Presentation (IP) if it were a slide deck, or more generally as a Regulatory Filing (RNS) or an announcement related to ongoing operations. Since it is a formal announcement of a significant operational milestone (completion of recruitment and safety clearance) that is highly relevant to investors but doesn't fit the specific definitions of ER, AR, or 10-K, and it is not a proxy statement (DEF 14A) or a management discussion (MDA), the most appropriate general category for significant, non-standard operational updates that are not explicitly defined elsewhere is Regulatory Filings (RNS). However, given the detailed nature of the clinical update, it strongly resembles an Investor Presentation (IP) or a specific operational update. Since 'IP' is defined as a detailed presentation focusing on financials, strategy, and market position, and this document heavily focuses on clinical strategy and market potential, 'IP' is a strong candidate. But, as it is structured as a news release announcing progress, 'RNS' (Regulatory Filings/General Announcement) serves as the best fit for a standard press release detailing clinical trial progress that isn't a formal financial report or a specific management/board change.
2016-10-27 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.